These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37678101)

  • 41. Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.
    Quattrone A; Morelli M; Vescio B; Nigro S; Le Piane E; Sabatini U; Caracciolo M; Vescio V; Quattrone A; Barbagallo G; Stanà C; Nicoletti G; Arabia G; Nisticò R; Novellino F; Salsone M
    Mov Disord; 2019 Apr; 34(4):487-495. PubMed ID: 30759325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dysphagia in Progressive Supranuclear Palsy.
    Clark HM; Stierwalt JAG; Tosakulwong N; Botha H; Ali F; Whitwell JL; Josephs KA
    Dysphagia; 2020 Aug; 35(4):667-676. PubMed ID: 31676923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Klietz M; Mahmoudi N; Maudsley AA; Sheriff S; Bronzlik P; Almohammad M; Nösel P; Wegner F; Höglinger GU; Lanfermann H; Ding XQ
    Mov Disord; 2023 Aug; 38(8):1503-1514. PubMed ID: 37289057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visual fixation suppression of caloric nystagmus in progressive supranuclear palsy - A comparison with Parkinson's disease.
    Naito R; Watanabe Y; Naito A; Sugasawa K; Nakata Y; Kamiyama T; Okiyama R; Yokochi F; Isozaki E; Yamasoba T; Takahashi K
    J Vestib Res; 2023; 33(6):385-401. PubMed ID: 37599554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy.
    Nigro S; Arabia G; Antonini A; Weis L; Marcante A; Tessitore A; Cirillo M; Tedeschi G; Zanigni S; Calandra-Buonaura G; Tonon C; Pezzoli G; Cilia R; Zappia M; Nicoletti A; Cicero CE; Tinazzi M; Tocco P; Cardobi N; Quattrone A
    Eur Radiol; 2017 Jun; 27(6):2665-2675. PubMed ID: 27761709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
    Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discriminating features of gait performance in progressive supranuclear palsy.
    Amano S; Skinner JW; Lee HK; Stegemöller EL; Hack N; Akbar U; Vaillancourt D; McFarland NR; Hass CJ
    Parkinsonism Relat Disord; 2015 Aug; 21(8):888-93. PubMed ID: 26032992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Speech acoustic indices for differential diagnosis between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Daoudi K; Das B; Tykalova T; Klempir J; Rusz J
    NPJ Parkinsons Dis; 2022 Oct; 8(1):142. PubMed ID: 36302780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of intensive speech rate and intonation therapy on intelligibility in Parkinson's disease.
    Martens H; Van Nuffelen G; Dekens T; Hernández-Díaz Huici M; Kairuz Hernández-Díaz HA; De Letter M; De Bodt M
    J Commun Disord; 2015; 58():91-105. PubMed ID: 26519934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.
    Azuma M; Hirai T; Nakaura T; Kitajima M; Yamashita S; Hashimoto M; Yamada K; Uetani H; Yamashita Y; Wang Y
    J Neurol Sci; 2019 Nov; 406():116443. PubMed ID: 31634718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
    Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L
    Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy.
    Hara K; Watanabe H; Ito M; Tsuboi T; Watanabe H; Nakamura R; Senda J; Atsuta N; Adachi H; Aiba I; Naganawa S; Sobue G
    Parkinsonism Relat Disord; 2014 Feb; 20(2):157-61. PubMed ID: 24172606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders.
    Watanabe Y; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Uchiyama T; Kadowaki T; Matsubara T; Hirata K
    Intern Med; 2017 Nov; 56(21):2871-2878. PubMed ID: 28943542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.
    Constantinides VC; Souvatzoglou M; Paraskevas GP; Chalioti M; Stefanis L; Kapaki E
    Neurol Sci; 2023 May; 44(5):1613-1623. PubMed ID: 36658411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.
    Quattrone A; Nicoletti G; Messina D; Fera F; Condino F; Pugliese P; Lanza P; Barone P; Morgante L; Zappia M; Aguglia U; Gallo O
    Radiology; 2008 Jan; 246(1):214-21. PubMed ID: 17991785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Santangelo G; Cuoco S; Pellecchia MT; Erro R; Barone P; Picillo M
    J Neurol; 2018 Nov; 265(11):2602-2613. PubMed ID: 30178175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy.
    Clark HM; Utianski RL; Ali F; Botha H; Whitwell JL; Josephs KA
    Am J Speech Lang Pathol; 2021 Jun; 30(3S):1361-1372. PubMed ID: 33719524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
    Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
    Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease.
    Price S; Paviour D; Scahill R; Stevens J; Rossor M; Lees A; Fox N
    Neuroimage; 2004 Oct; 23(2):663-9. PubMed ID: 15488416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.
    Stamelou M; Diehl-Schmid J; Hapfelmeier A; Kontaxopoulou D; Stefanis L; Oertel WH; Bhatia KP; Papageorgiou SG; Höglinger GU
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1264-8. PubMed ID: 26324212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.